$360m Deal-making CEO of Oxford-based Prosidion to Address BioTrinity

CEO of UK-based subsidiary of (OSI) Pharmaceuticals to present at a new biotechnology partnering conference which will showcase companies from the most successful biotech super-cluster in Europe, which has raised more in IPO, second round and private equity financing than any other region in recent years.

(PRWEB) January 29, 2007 -- Earlier this month, Colin Goddard, Ph.D., Chief Executive Officer of Prosidion's US-based parent company, OSI Pharmaceuticals, gave a very strong indication of his confidence in their UK subsidiary saying, "Under Anker Lundemose's leadership, our UK-based subsidiary, Prosidion, has established a portfolio of innovative drug candidates and demonstrated an ability to rapidly and effectively advance drug candidates to a clinical proof-of-concept."

Under Anker Lundemose's leadership, our UK-based subsidiary, Prosidion, has established a portfolio of innovative drug candidates and demonstrated an ability to rapidly and effectively advance drug candidates to a clinical proof-of-concept.

Prosidion is one of more than 25 exciting biotech companies which are going to be showcased at BioTrinity 2007, the annual biotech partnering meeting organised by OBN (Oxfordshire Bioscience Network), the "MassBio" of the Southern UK region.

With just two months until BioTrinity 2007 - is your name still missing from the list of over 100 companies already participating in BioTrinity?

BioTrinity has seen a very early adoption of the larger players in the industry such as Merck, Pfizer, Genzyme, BMS, Eli Lilly and AstraZeneca. Considerable interest in BioTrinity's VC session has also been shown by companies such as SR-one, Novartis Venture Fund, 3i and Oxford Capital Partners. Exhibitor spaces were sold-out even before Christmas.

The preliminary programme has been published online and is constantly developing, with the confirmed participation of many exciting young companies such as PIraMed, ReNeuron, VASTox, Chroma Therapeutics, Surface Therapeutics and Glide Pharma. A very good level of international interest has also been generated by companies and government agencies from North America, Europe and Asia.

Dr Jon Rees, Director of Oxfordshire Bioscience Network said, "Prosidion's deal with Eli Lilly is a highly significant step in the growth and development of the South East biotech cluster, following hot on the heels of the acquisition of PowderMed by Pfizer late last year, together with record levels of fundraising of biotech companies in the region between 2004-6. What we are seeing in the recent financings of biotech companies by the market, and the levels of investment in Science Park Development around Oxfordshire with around 200,000sq ft under development, is a very clear sign of the bullish confidence in the prospects of our maturing drug discovery sector."

Companies confirmed as already participating in BioTrinity:

3i Group Plc
a2sp Limited
AF Engineering Services Ltd
Amplion
Argenta Discovery Ltd
AS-Tec Chemicals Ltd
AstraZeneca Pharmaceuticals
Bench International
Beta Technology
BioPark Hertfordshire
BioProcess UK
Biotechnology Finance Advisory Service
Boult Wade Tennant
Bristol-Myers Squibb
Business Link Kent
Charles Russell LLP
Chroma Therapeutics
CMS Cameron McKenna LLP
Cobra Biomanufacturing
Complete Legal
Constella Group Ltd
Cranmer Lawrence & Company
De Facto Communications
Diagnox
Dionex UK ltd.
Drug Discovery Today
EBD Group
Eli Lilly & Company Ltd
Epidyme Ltd
Ernst & Young LLP
Evolutec
Thermo Fisher Scientific
Focus Insurance
Genzyme Therapeutics Ltd
Glide Pharmaceuticals
GlycoForm Ltd
Guildhay Ltd
Health Protection Agency
IBI Biosolutions (India)
Incentec Ltd
Intellidos Consulting
Interea International
Invest in Denmark
iQur Ltd
James Cowper
Josfred International Limited
Kent Bioscience Network
Lab Support UK Ltd
London Biotechnology Network
Manches LLP
Marks & Clerk
MedNet Pharmacelsus
Merck Sharp Dohme
Microtest Matrices Ltd
Millipore
Miller Insurance Services (UK) Limited
M-Scan
National Physical Laboratories
Novartis Venture Fund
Novolytics Limited
On Assignment Lab Support UK
(OSI) Prosidion
Owen Mumford Ltd
Oxford BioMedica
Oxford Capital Partners
Oxford Expression Technologies
Oxford Science Park
Oxfordshire Bioscience Network
OXiGENE Inc.
Oxygen Healthcare Limited
Pall Life Sciences
PAREXEL Consulting
PerkinElmer
Pfizer
PharmaVentures Ltd
Phase7
Phynova
PIraMed Ltd
Prosonix Limited
Quintiles Ltd
Reed Scientific
ReNeuron Group plc
SAFC Pharma
South East Medical Devices Network (SEMDN)
S.R. One
School of Life Sciences, Oxford Brookes University
South East Health Technologies Alliance
Spirogen Ltd
Stimutran-SME
Surface Therapeutics
Surrey Enterprise Hub
Takeda Global R&D Centre
Tessella Support Services plc
Thames Valley Life Science Network (TVLSN)
TTP LabTech
Ubichem PLC
University of Brighton
University of Southampton
University of the West of England, Bristol
UK Trade and Investment
VASTox Ltd
Vivacta Ltd
VWR Biosciences

###

Post Comment:
Trackback URL: http://ca.prweb.com/pingpr.php/VGhpci1aZXRhLUVtcHQtWmV0YS1NYWduLVplcm8=

astrazeneca biomedica biotechnology biotrinity eli lilly genzyme merck partnering prosidion pfizer

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web